Skip to content
lifestyle.buyersdesire.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
March 16, 2026
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
March 12, 2026
Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)
March 11, 2026
Lilly to participate in TD Cowen’s 46th Annual Health Care Conference
March 10, 2026
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
March 10, 2026
Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
March 10, 2026
Lilly to acquire Orna Therapeutics to advance cell therapies
March 9, 2026
←
Previous Page
1
…
4
5
6